Take advantage of this opportunity to discuss the genetic underpinnings of metabolic dysfunction–associated steatotic liver disease (MASLD) with topic experts. Faculty address and review the genetic risk and protective factors for MASLD onset, development, and progression. Presenters also highlight the role of genetic risk scores in MASLD.
Women living with liver disease often have concerns not experienced by men with liver disease. Join experts to discuss women's health among those living with liver disease. Faculty discuss and review the role of estrogens in liver disease; the impact of liver disease in the safe use of contraception and hormone replacement therapy; and pregnancy and family planning.
Risk stratification in chronic liver disease is evolving from static fibrosis staging toward dynamic prediction of cirrhosis progression, portal hypertension, and clinical decompensation. Learn from topic experts who examine how established and emerging noninvasive tools—using a physiology-driven approach—can more accurately capture the determinants of disease progression. Disscussants integrate conventional serum and elastography-based noninvasive tests with emerging hemodynamic imaging, including magnetic resonance flow models (eg, magnetic resonance phase contrast vastly undersampled imaging with projection reconstruction; MR PC-VIPR) to highlight their complementary roles in assessment of portal hypertension and decompensation risk.
Through expert commentary and case-based discussion, participants examine how combining structural and functional biomarkers can improve prediction of first decompensation, adverse clinical outcomes, and therapeutic responses. Faculty emphasize practical application, limitations of current evidence, and future directions for incorporating advanced noninvasive tools into longitudinal patient management and accelerating outcome-driven clinical trials in cirrhosis.
Glucagon-like peptide-1 (GLP-1) drugs—including both GLP-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide [GIP] receptor agonists—have become ubiquitous in the public arena. These drugs represent some of the most promising treatment options for persons with metabolic dysfunction–associated steatohepatitis (MASH) because they treat the underlying comorbidities (obesity and diabetes) as well as MASH. Additionally, they have proven cardiovascular benefits. Persons with MASH want reliable information on whether they are eligible to be treated with GLP-1 drugs; what to expect in terms of response; how to monitor response; and how to manage potential side effects.
Key topics addressed by speakers include:
Artificial Intelligence (AI) and machine learning (ML) tools are increasingly marketed for clinical use. Yet many clinicians, researchers, and health system leaders lack structured approaches to critically evaluate these models, understand their real-world implications, and plan for responsible scale. Presented as a partnership between the Clinical Informatics and Digital Health Special Interest Group and the Clinical Research Committee, this session equips learners with practical frameworks to assess AI/ML models; examines the realities of implementation in clinical environments; and explores future-facing strategies for scaling AI while maintaining safety, equity, and trust through the presentation and discussion of real-world examples from clinical research applying AI and ML methodologies.The session concludes with an interactive panel discussion on how to translate AI/ML use from theory into clinical research and practice.
Session organizers aim to equip participants with the knowledge and tools needed to describe appropriate use cases of AI/ML, to understand the implications of employing these approaches, and to think critically about the performance of different AI/ML algorithms in clinical research through a generalized assessment framework.
Accurate liver diagnosis demands confident imaging interpretation, selective biopsy use, and smart application of specialized tests. This case-based session delivers practical skills in 3 areas: (1) radiology for nonradiologists; (2) biopsy in the era of noninvasive tests; and (3) uncommon diagnostics. Attendees gain actionable checklists, algorithms, and strategies for immediate clinical application. Designed for hepatology clinicians and multidisciplinary teams, this session emphasizes real-world decision-making and interactive questions and answers.
This cutting-edge session focuses on current and upcoming treatments for hepatitis B and hepatitis D. Presenters also discuss important updates from recent viral hepatitis guidelines across the world regarding the management of hepatitis B, and provide insight into global pediatric issues related to hepatitis B and hepatitis D.
Metabolic syndrome and obesity are increasingly prevalent among persons with liver disease, particularly in those with metabolic dysfunction–associated steatotic liver disease (MASLD). As hepatologists incorporate powerful incretin therapies into their treatment arsenal, understanding their optimal use in diverse and special populations becomes essential—and is the focus of this session.
Presenters discuss emerging evidence that highlights the importance of tailoring these therapies to unique patient groups including: (1) liver transplant candidates, recipients, and donors; (2) women with reproductive considerations; (3) Black, Indigenous, and People of Color (BIPOC) populations; and (4) nonobese individuals with metabolic syndrome. Speakers explore the latest insights and practical approaches for applying incretin therapies in these distinct populations, aiming to guide clinicians in personalized and effective management strategies.
The definition and research framework for acute-on-chronic liver failure (ACLF) remain fragmented across different regions of the world. The primary objective is to bring together global experts, field leaders, and researchers to work collaboratively toward a unified understanding of ACLF. ACLF should be recognized as a single disease entity—similar to acute liver failure (ALF) or other well-defined disease etiologies—with clearly established diagnostic criteria, standardized therapeutic algorithms, and uniform patient management pathways. Such harmonization will facilitate collaborative research, attract industry support, enable competitive research funding, and, most importantly, represent a critical step toward improving patient survival and outcomes in this high-mortality condition. Key topics addressed in this session include:
Presenters highlight recent advances in the management of liver diseases commonly encountered in general gastroenterology and community-based inpatient practices. Using a case-based approach, speakers address: